Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer

Background The prognostic significance of various systemic inflammation‐based markers has been explored in different cancers. These markers can be used to assist with decision‐making in oncology clinics. Aim The aim of this study was to investigate the prognostic significance of three systemic infla...

Full description

Saved in:
Bibliographic Details
Published inInternal medicine journal Vol. 44; no. 7; pp. 676 - 682
Main Authors Martin, H. L., Ohara, K., Kiberu, A., Van Hagen, T., Davidson, A., Khattak, M. A.
Format Journal Article
LanguageEnglish
Published Australia Blackwell Publishing Ltd 01.07.2014
Subjects
Adult
Aged
Aged, 80 and over
biomarker
Biomarkers - blood
cancer
chemotherapy
Female
Humans
inflammation
Inflammation - blood
Inflammation - diagnosis
Inflammation - mortality
Inflammation Mediators - blood
Male
Middle Aged
pancreas
Pancreatic Neoplasms - blood
Pancreatic Neoplasms - diagnosis
Pancreatic Neoplasms - mortality
Prognosis
Retrospective Studies
Survival Rate - trends
cancer
biomarker
inflammation
chemotherapy
prognosis
pancreas
Online AccessGet full text

Cover

Abstract Background The prognostic significance of various systemic inflammation‐based markers has been explored in different cancers. These markers can be used to assist with decision‐making in oncology clinics. Aim The aim of this study was to investigate the prognostic significance of three systemic inflammation‐based factors: neutrophil‐lymphocyte ratio (NLR), platelet‐lymphocyte ratio (PLR) and modified Glasgow Prognostic Score (mGPS) in patients with advanced pancreatic cancer. Methods Data were collected retrospectively for advanced pancreatic cancer patients treated between 1 January 2008 and 31 December 2012 at the Royal Perth Hospital. The ratios were dichotomised as <5 versus ≥5 for NLR and <200 versus ≥200 for PLR. Modified Glasgow Prognostic Scores were scored as: mGPS ‘0’ = both C‐reactive protein (CRP) and albumin normal, mGPS ‘1’ = elevated CRP < 10 mg/L and mGPS ‘2’ = both elevated CRP > 10 mg/L and albumin < 35 g/L. Univariate and multivariate analyses were carried out. Results Data were evaluable for 124 patients. Median survivals based on the three inflammation‐based prognostic markers evaluated were: NLR <5 versus ≥5 = 8.5 months versus 2.6 months respectively (P = 0.0007; hazard ratio (HR) 1.81), PLR <200 versus ≥200 = 9.1 months versus 4 months respectively (P = 0.007; HR 1.64) and mGPS score 1, 2, 3 = 8.3 months, 9.6 months and 1.8 months respectively (P = 0.0004). Besides Eastern Cooperative Oncology Group performance status, NLR, PLR and mGPS were significant independent prognostic markers both on univariate as well as multivariate analysis. Conclusions Our findings suggest that the NLR, PLR and mGPS derived from routine blood tests can be used as clinically meaningful biomarkers to stratify advanced pancreatic cancer patients into different prognostic groups.
AbstractList BACKGROUNDThe prognostic significance of various systemic inflammation-based markers has been explored in different cancers. These markers can be used to assist with decision-making in oncology clinics.AIMThe aim of this study was to investigate the prognostic significance of three systemic inflammation-based factors: neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and modified Glasgow Prognostic Score (mGPS) in patients with advanced pancreatic cancer.METHODSData were collected retrospectively for advanced pancreatic cancer patients treated between 1 January 2008 and 31 December 2012 at the Royal Perth Hospital. The ratios were dichotomised as <5 versus ≥5 for NLR and <200 versus ≥200 for PLR. Modified Glasgow Prognostic Scores were scored as: mGPS '0' = both C-reactive protein (CRP) and albumin normal, mGPS '1' = elevated CRP < 10 mg/L and mGPS '2' = both elevated CRP > 10 mg/L and albumin < 35 g/L. Univariate and multivariate analyses were carried out.RESULTSData were evaluable for 124 patients. Median survivals based on the three inflammation-based prognostic markers evaluated were: NLR <5 versus ≥5 = 8.5 months versus 2.6 months respectively (P = 0.0007; hazard ratio (HR) 1.81), PLR <200 versus ≥200 = 9.1 months versus 4 months respectively (P = 0.007; HR 1.64) and mGPS score 1, 2, 3 = 8.3 months, 9.6 months and 1.8 months respectively (P = 0.0004). Besides Eastern Cooperative Oncology Group performance status, NLR, PLR and mGPS were significant independent prognostic markers both on univariate as well as multivariate analysis.CONCLUSIONSOur findings suggest that the NLR, PLR and mGPS derived from routine blood tests can be used as clinically meaningful biomarkers to stratify advanced pancreatic cancer patients into different prognostic groups.
Background The prognostic significance of various systemic inflammation‐based markers has been explored in different cancers. These markers can be used to assist with decision‐making in oncology clinics. Aim The aim of this study was to investigate the prognostic significance of three systemic inflammation‐based factors: neutrophil‐lymphocyte ratio (NLR), platelet‐lymphocyte ratio (PLR) and modified Glasgow Prognostic Score (mGPS) in patients with advanced pancreatic cancer. Methods Data were collected retrospectively for advanced pancreatic cancer patients treated between 1 January 2008 and 31 December 2012 at the Royal Perth Hospital. The ratios were dichotomised as <5 versus ≥5 for NLR and <200 versus ≥200 for PLR. Modified Glasgow Prognostic Scores were scored as: mGPS ‘0’ = both C‐reactive protein (CRP) and albumin normal, mGPS ‘1’ = elevated CRP < 10 mg/L and mGPS ‘2’ = both elevated CRP > 10 mg/L and albumin < 35 g/L. Univariate and multivariate analyses were carried out. Results Data were evaluable for 124 patients. Median survivals based on the three inflammation‐based prognostic markers evaluated were: NLR <5 versus ≥5 = 8.5 months versus 2.6 months respectively (P = 0.0007; hazard ratio (HR) 1.81), PLR <200 versus ≥200 = 9.1 months versus 4 months respectively (P = 0.007; HR 1.64) and mGPS score 1, 2, 3 = 8.3 months, 9.6 months and 1.8 months respectively (P = 0.0004). Besides Eastern Cooperative Oncology Group performance status, NLR, PLR and mGPS were significant independent prognostic markers both on univariate as well as multivariate analysis. Conclusions Our findings suggest that the NLR, PLR and mGPS derived from routine blood tests can be used as clinically meaningful biomarkers to stratify advanced pancreatic cancer patients into different prognostic groups.
Abstract Background The prognostic significance of various systemic inflammation‐based markers has been explored in different cancers. These markers can be used to assist with decision‐making in oncology clinics. Aim The aim of this study was to investigate the prognostic significance of three systemic inflammation‐based factors: neutrophil‐lymphocyte ratio ( NLR ), platelet‐lymphocyte ratio ( PLR ) and modified G lasgow P rognostic S core (m GPS ) in patients with advanced pancreatic cancer. Methods Data were collected retrospectively for advanced pancreatic cancer patients treated between 1 J anuary 2008 and 31 D ecember 2012 at the R oyal P erth H ospital. The ratios were dichotomised as <5 versus ≥5 for NLR and <200 versus ≥200 for PLR . Modified G lasgow P rognostic S cores were scored as: m GPS ‘0’ = both C ‐reactive protein ( CRP ) and albumin normal, m GPS ‘1’ = elevated CRP < 10 mg/L and m GPS ‘2’ = both elevated CRP > 10 mg/L and albumin < 35 g/L. Univariate and multivariate analyses were carried out. Results Data were evaluable for 124 patients. Median survivals based on the three inflammation‐based prognostic markers evaluated were: NLR <5 versus ≥5 = 8.5 months versus 2.6 months respectively ( P = 0.0007; hazard ratio ( HR ) 1.81), PLR <200 versus ≥200 = 9.1 months versus 4 months respectively ( P = 0.007; HR 1.64) and m GPS score 1, 2, 3 = 8.3 months, 9.6 months and 1.8 months respectively ( P = 0.0004). Besides E astern C ooperative O ncology G roup performance status, NLR , PLR and m GPS were significant independent prognostic markers both on univariate as well as multivariate analysis. Conclusions Our findings suggest that the NLR , PLR and m GPS derived from routine blood tests can be used as clinically meaningful biomarkers to stratify advanced pancreatic cancer patients into different prognostic groups.
The prognostic significance of various systemic inflammation-based markers has been explored in different cancers. These markers can be used to assist with decision-making in oncology clinics. The aim of this study was to investigate the prognostic significance of three systemic inflammation-based factors: neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and modified Glasgow Prognostic Score (mGPS) in patients with advanced pancreatic cancer. Data were collected retrospectively for advanced pancreatic cancer patients treated between 1 January 2008 and 31 December 2012 at the Royal Perth Hospital. The ratios were dichotomised as <5 versus ≥5 for NLR and <200 versus ≥200 for PLR. Modified Glasgow Prognostic Scores were scored as: mGPS '0' = both C-reactive protein (CRP) and albumin normal, mGPS '1' = elevated CRP < 10 mg/L and mGPS '2' = both elevated CRP > 10 mg/L and albumin < 35 g/L. Univariate and multivariate analyses were carried out. Data were evaluable for 124 patients. Median survivals based on the three inflammation-based prognostic markers evaluated were: NLR <5 versus ≥5 = 8.5 months versus 2.6 months respectively (P = 0.0007; hazard ratio (HR) 1.81), PLR <200 versus ≥200 = 9.1 months versus 4 months respectively (P = 0.007; HR 1.64) and mGPS score 1, 2, 3 = 8.3 months, 9.6 months and 1.8 months respectively (P = 0.0004). Besides Eastern Cooperative Oncology Group performance status, NLR, PLR and mGPS were significant independent prognostic markers both on univariate as well as multivariate analysis. Our findings suggest that the NLR, PLR and mGPS derived from routine blood tests can be used as clinically meaningful biomarkers to stratify advanced pancreatic cancer patients into different prognostic groups.
Author Khattak, M. A.
Van Hagen, T.
Davidson, A.
Ohara, K.
Martin, H. L.
Kiberu, A.
Author_xml – sequence: 1
  givenname: H. L.
  surname: Martin
  fullname: Martin, H. L.
  organization: Department of Medical Oncology, Royal Perth Hospital, Western Australia, Perth, Australia
– sequence: 2
  givenname: K.
  surname: Ohara
  fullname: Ohara, K.
  organization: Department of Medical Oncology, Royal Perth Hospital, Western Australia, Perth, Australia
– sequence: 3
  givenname: A.
  surname: Kiberu
  fullname: Kiberu, A.
  organization: Department of Medical Oncology, Royal Perth Hospital, Western Australia, Perth, Australia
– sequence: 4
  givenname: T.
  surname: Van Hagen
  fullname: Van Hagen, T.
  organization: Department of Medical Oncology, Royal Perth Hospital, Western Australia, Perth, Australia
– sequence: 5
  givenname: A.
  surname: Davidson
  fullname: Davidson, A.
  organization: Department of Medical Oncology, Royal Perth Hospital, Western Australia, Perth, Australia
– sequence: 6
  givenname: M. A.
  surname: Khattak
  fullname: Khattak, M. A.
  email: adnan.khattak@health.wa.gov.au
  organization: Department of Medical Oncology, Royal Perth Hospital, Western Australia, Perth, Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24750233$$D View this record in MEDLINE/PubMed
BookMark eNp1kMtOwzAURC1URB-w4AdQlrBIa8dOHC9RRR-oQEFULC3HcVBKEhc7LfTvcZu2O7y51ty5I83pglalKwXANYJ95N4gL5d9FJAQn4EOIiT0Q8ZIa_8nPmQQt0HX2iWEiGJGLkA7IDSEAcYdsJgb_VlpW-fS24hirTydeXZra1U6Ja-yQpSlqHNd-YmwKvVKYb6UsW7liXQjKum0lRtGiV2G3CnmEpxnorDq6jB7YDF6eB9O_NnLeDq8n_mSBAz7LBYBTojEMcsCGlEkIwITRoVCIYQQZwTDFMZYwTSjNCYsioMIJ1II4qpAhnvgtsldGf29VrbmZW6lKgpRKb22HIWuKKbEde2Bu8YqjbbWqIyvTO7KbDmCfEeRO4p8T9F5bw6x66RU6cl5xOYMg8bwkxdq-38Snz49HiP95iJ3aH9PFw4mjyimIf94HnM2mr3Ox5M3PsR_n-2Lzw
CitedBy_id crossref_primary_10_14701_kjhbps_2014_18_4_138
crossref_primary_10_18632_oncotarget_20871
crossref_primary_10_3109_21681805_2015_1136677
crossref_primary_10_1186_s12876_018_0748_4
crossref_primary_10_18632_oncotarget_15281
crossref_primary_10_1177_0885066617753389
crossref_primary_10_23736_S2724_5691_21_08544_0
crossref_primary_10_1097_SLA_0000000000001988
crossref_primary_10_3348_kjr_2022_0277
crossref_primary_10_1007_s00432_020_03361_0
crossref_primary_10_1007_s11604_023_01482_3
crossref_primary_10_1016_j_cca_2018_01_024
crossref_primary_10_2217_fon_2017_0556
crossref_primary_10_3390_cancers14205068
crossref_primary_10_1007_s00268_017_4027_2
crossref_primary_10_1007_s00345_016_1940_1
crossref_primary_10_1177_1559325820942065
crossref_primary_10_1186_s12935_020_01558_4
crossref_primary_10_3390_diagnostics13203270
crossref_primary_10_1155_2018_2373868
crossref_primary_10_1186_s12885_016_2671_9
crossref_primary_10_3892_ol_2019_10809
crossref_primary_10_5009_gnl18445
crossref_primary_10_3892_ol_2018_9285
crossref_primary_10_1097_MD_0000000000011002
crossref_primary_10_1002_cncr_33420
crossref_primary_10_1038_s41388_023_02647_0
crossref_primary_10_1097_MPA_0000000000001878
crossref_primary_10_18632_aging_202357
crossref_primary_10_1007_s00595_015_1206_3
crossref_primary_10_1016_j_jocn_2021_01_036
crossref_primary_10_3892_ol_2016_4381
crossref_primary_10_1007_s10585_019_09996_9
crossref_primary_10_1177_1177271919851505
crossref_primary_10_1245_s10434_018_6699_8
crossref_primary_10_1007_s00595_016_1308_6
crossref_primary_10_1097_MD_0000000000003582
crossref_primary_10_1097_MD_0000000000009247
crossref_primary_10_2147_JIR_S385328
crossref_primary_10_1155_2020_5701949
crossref_primary_10_1097_COC_0000000000000687
crossref_primary_10_3389_fonc_2018_00078
crossref_primary_10_3390_cancers11010057
crossref_primary_10_1111_apt_14046
crossref_primary_10_1038_srep11026
crossref_primary_10_1245_s10434_019_08047_7
crossref_primary_10_1016_j_biocel_2016_03_009
crossref_primary_10_1002_jso_23900
crossref_primary_10_1002_jso_25209
crossref_primary_10_1371_journal_pone_0262439
crossref_primary_10_1097_MD_0000000000009616
crossref_primary_10_3390_cancers15082367
crossref_primary_10_1590_0102_672020180001e1366
crossref_primary_10_1097_MD_0000000000001012
crossref_primary_10_1186_s12885_021_09144_1
crossref_primary_10_5009_gnl17216
crossref_primary_10_3892_mco_2017_1527
crossref_primary_10_1111_jgh_14926
crossref_primary_10_1016_j_cca_2018_06_019
crossref_primary_10_1111_ans_15030
crossref_primary_10_1111_ajco_13325
crossref_primary_10_1016_j_asjsur_2021_08_011
crossref_primary_10_1245_s10434_019_08056_6
crossref_primary_10_1016_j_critrevonc_2020_102962
crossref_primary_10_18632_oncotarget_27518
crossref_primary_10_1016_j_cca_2018_04_023
crossref_primary_10_1007_s12032_018_1219_z
crossref_primary_10_1097_COC_0000000000000263
crossref_primary_10_1016_j_clnu_2015_08_005
crossref_primary_10_1016_j_surg_2015_03_043
crossref_primary_10_1155_2022_7473649
crossref_primary_10_1016_j_hbpd_2019_03_010
crossref_primary_10_1097_JP9_0000000000000022
crossref_primary_10_1155_2018_9745601
crossref_primary_10_1158_2159_8290_CD_15_0843
crossref_primary_10_1245_s10434_019_08161_6
crossref_primary_10_1016_j_arr_2021_101398
crossref_primary_10_1007_s10637_018_0681_y
crossref_primary_10_1371_journal_pone_0178777
crossref_primary_10_3748_wjg_v21_i9_2807
crossref_primary_10_32322_jhsm_1056614
crossref_primary_10_5009_gnl18271
crossref_primary_10_1080_07357907_2020_1863419
Cites_doi 10.3322/caac.20107
10.1056/NEJMoa1110352
10.1016/j.amjsurg.2009.08.041
10.1016/j.ctrv.2012.08.003
10.1089/10799900260286623
10.1007/BF02482964
10.3802/jgo.2012.23.4.265
10.3747/co.v17i4.567
10.1097/01.sla.0000259391.84304.2b
10.1056/NEJM198612253152606
10.1056/NEJM199902113400607
10.1023/B:AGEN.0000029415.62384.ba
10.1007/s00268-011-0984-z
10.1038/nature01322
10.1016/j.jhep.2012.08.017
10.1016/j.critrevonc.2013.03.010
10.1016/j.cell.2011.02.013
10.1016/S0002-9440(10)65149-8
10.1016/S0140-6736(00)04046-0
10.1016/j.jamcollsurg.2004.01.022
10.1006/gyno.1998.5121
10.1016/j.cytogfr.2007.01.015
10.1097/00000658-199602000-00006
10.1007/s12032-012-0226-8
10.1038/sj.bjc.6606087
10.1056/NEJMoa1304369
10.2217/fon.09.136
10.1097/01.mpa.0000188305.90290.50
10.3181/00379727-212-44008
10.1056/NEJMoa1011923
10.1038/nature07205
10.1038/bjc.2013.332
10.1097/00000421-200304000-00007
10.1016/j.amjsurg.2007.12.057
10.1016/j.bpg.2007.11.007
10.1038/bjc.2011.100
ContentType Journal Article
Copyright 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians
2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.
Copyright_xml – notice: 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians
– notice: 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1111/imj.12453
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1445-5994
EndPage 682
ExternalDocumentID 10_1111_imj_12453
24750233
IMJ12453
ark_67375_WNG_9FLQPGHR_C
Genre article
Journal Article
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OC
29J
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAVGM
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABHUG
ABJNI
ABLJU
ABPTK
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXME
ACXQS
ADAWD
ADBBV
ADBTR
ADDAD
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFVGU
AFZJQ
AGJLS
AHBTC
AIACR
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HVGLF
HZI
HZ~
IHE
IX1
J0M
J5H
K48
KBYEO
KTM
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
RJQFR
ROL
RX1
SUPJJ
TEORI
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOQ
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
YFH
ZGI
ZZTAW
~IA
~WT
AITYG
HGLYW
OIG
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c4293-98a23b4c389f27671c640b97ae150003f430d083e0df7784968263bcaa4017093
IEDL.DBID DR2
ISSN 1444-0903
IngestDate Fri Aug 16 22:06:05 EDT 2024
Fri Aug 23 00:34:11 EDT 2024
Sat Sep 28 07:54:15 EDT 2024
Sat Aug 24 01:03:00 EDT 2024
Wed Jan 17 05:02:12 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords cancer
biomarker
inflammation
chemotherapy
prognosis
pancreas
Language English
License 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4293-98a23b4c389f27671c640b97ae150003f430d083e0df7784968263bcaa4017093
Notes ark:/67375/WNG-9FLQPGHR-C
ArticleID:IMJ12453
istex:9B4F308FB79CA3B52E6A36F703850BE2C8790F51
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 24750233
PQID 1547537402
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_1547537402
crossref_primary_10_1111_imj_12453
pubmed_primary_24750233
wiley_primary_10_1111_imj_12453_IMJ12453
istex_primary_ark_67375_WNG_9FLQPGHR_C
PublicationCentury 2000
PublicationDate July 2014
PublicationDateYYYYMMDD 2014-07-01
PublicationDate_xml – month: 07
  year: 2014
  text: July 2014
PublicationDecade 2010
PublicationPlace Australia
PublicationPlace_xml – name: Australia
PublicationTitle Internal medicine journal
PublicationTitleAlternate Intern Med J
PublicationYear 2014
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol 2012; 23: 265-273.
Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010; 200: 197-203.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545.
Von Hoff DD, Ervin T, Arena FP, Chiorean G, Infante J, Moore M et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703.
Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659.
Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013; 88: 218-230.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg 1996; 223: 147-153.
Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366: 610-618.
Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
McKay CJ, Glen P, McMillan DC. Chronic inflammation and pancreatic cancer. Best Prac Res Clin Gastroenterol 2008; 22: 65-73.
Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol 2012; 29: 3092-3100.
Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003; 26: 135-140.
McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013; 39: 534-540.
Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013; 58: 58-64.
Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004; 198: 737-741.
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006; 32: 22-28.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002; 22: 913-922.
Dabrow MB, Francesco MR, McBrearty FX, Caradonna S. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 1998; 71: 29-37.
Romano F, Uggeri F, Crippa S, Di Stefano G, Scotti M, Scaini A et al. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers. J Exp Clin Cancer Res 2004; 23: 195-200.
Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013; 109: 416-421.
Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003; 6: 283-287.
Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 2007; 18: 171-182.
Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009; 197: 466-472.
Ozaki H, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, Nakayama T et al. The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today 1999; 29: 16-22.
Qian X, Tuszynski GP. Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med 1996; 212: 199-207.
Zahorec R. Ratio of neutrophil to lymphocyte counts - rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5-14.
Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi 1984; 85: 1001-1005.
Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011; 104: 1288-1295.
Griffanti-Bartoli F, Arnone GB, Ceppa P, Ravera G, Carrabetta S, Civalleri D. Malignant tumors in the head of the pancreas and the periampullary region. Diagnostic and prognostic aspects. Anticancer Res 1994; 14: 657-666.
Kasymjanova G, MacDonald N, Agulnik JS, Cohen V, Pepe C, Kreisman H et al. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol 2010; 17: 52-58.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 1999; 155: 537-547.
Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR, Berry DP. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg 2011; 35: 868-872.
Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011; 104: 726-734.
Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6: 149-163.
Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246: 52-60.
2007; 246
1986; 315
2007; 18
1984; 85
2001; 102
2012; 366
2013; 88
2013; 109
2006; 32
1999; 29
2010; 17
2013; 369
2010; 200
2004; 23
2011; 61
1999; 340
2011; 35
2009; 197
1996; 223
2011; 104
2004; 198
2013; 58
2013; 39
2003; 6
2002; 420
2002; 22
1994; 14
2003; 26
2012; 29
2008; 22
1999; 155
2008; 454
1998; 71
2012; 23
1996; 212
2001; 357
2011; 364
2011; 144
2010; 6
e_1_2_6_10_1
e_1_2_6_31_1
e_1_2_6_30_1
e_1_2_6_19_1
Zahorec R (e_1_2_6_26_1) 2001; 102
e_1_2_6_13_1
e_1_2_6_36_1
e_1_2_6_14_1
e_1_2_6_35_1
e_1_2_6_11_1
e_1_2_6_34_1
e_1_2_6_12_1
e_1_2_6_33_1
e_1_2_6_17_1
e_1_2_6_18_1
e_1_2_6_39_1
e_1_2_6_15_1
e_1_2_6_38_1
e_1_2_6_16_1
Onodera T (e_1_2_6_21_1) 1984; 85
e_1_2_6_37_1
e_1_2_6_20_1
e_1_2_6_41_1
Griffanti‐Bartoli F (e_1_2_6_6_1) 1994; 14
e_1_2_6_40_1
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_5_1
Romano F (e_1_2_6_32_1) 2004; 23
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_25_1
e_1_2_6_24_1
e_1_2_6_3_1
e_1_2_6_23_1
e_1_2_6_2_1
e_1_2_6_22_1
e_1_2_6_29_1
e_1_2_6_28_1
e_1_2_6_27_1
References_xml – volume: 104
  start-page: 1288
  year: 2011
  end-page: 1295
  article-title: Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer
  publication-title: Br J Cancer
– volume: 26
  start-page: 135
  year: 2003
  end-page: 140
  article-title: Levels of serum cytokines and acute phase proteins in patients with essential and cancer‐related thrombocytosis
  publication-title: Am J Clin Oncol
– volume: 144
  start-page: 646
  year: 2011
  end-page: 674
  article-title: Hallmarks of cancer: the next generation
  publication-title: Cell
– volume: 29
  start-page: 3092
  year: 2012
  end-page: 3100
  article-title: Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer
  publication-title: Med Oncol
– volume: 364
  start-page: 1817
  year: 2011
  end-page: 1825
  article-title: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
  publication-title: N Engl J Med
– volume: 88
  start-page: 218
  year: 2013
  end-page: 230
  article-title: The systemic inflammation‐based neutrophil‐lymphocyte ratio: experience in patients with cancer
  publication-title: Crit Rev Oncol Hematol
– volume: 39
  start-page: 534
  year: 2013
  end-page: 540
  article-title: The systemic inflammation‐based Glasgow Prognostic Score: a decade of experience in patients with cancer
  publication-title: Cancer Treat Rev
– volume: 85
  start-page: 1001
  year: 1984
  end-page: 1005
  article-title: [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]
  publication-title: Nihon Geka Gakkai Zasshi
– volume: 18
  start-page: 171
  year: 2007
  end-page: 182
  article-title: Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape
  publication-title: Cytokine Growth Factor Rev
– volume: 155
  start-page: 537
  year: 1999
  end-page: 547
  article-title: Tumor‐associated transforming growth factor‐beta and interleukin‐10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients
  publication-title: Am J Pathol
– volume: 104
  start-page: 726
  year: 2011
  end-page: 734
  article-title: An inflammation‐based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study
  publication-title: Br J Cancer
– volume: 14
  start-page: 657
  year: 1994
  end-page: 666
  article-title: Malignant tumors in the head of the pancreas and the periampullary region. Diagnostic and prognostic aspects
  publication-title: Anticancer Res
– volume: 197
  start-page: 466
  year: 2009
  end-page: 472
  article-title: Preoperative platelet‐lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma
  publication-title: Am J Surg
– volume: 200
  start-page: 197
  year: 2010
  end-page: 203
  article-title: Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil‐lymphocyte versus platelet‐lymphocyte ratio
  publication-title: Am J Surg
– volume: 366
  start-page: 610
  year: 2012
  end-page: 618
  article-title: Paraneoplastic thrombocytosis in ovarian cancer
  publication-title: N Engl J Med
– volume: 357
  start-page: 539
  year: 2001
  end-page: 545
  article-title: Inflammation and cancer: back to Virchow?
  publication-title: Lancet
– volume: 58
  start-page: 58
  year: 2013
  end-page: 64
  article-title: Neutrophil‐lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment
  publication-title: J Hepatol
– volume: 61
  start-page: 69
  year: 2011
  end-page: 90
  article-title: Global cancer statistics
  publication-title: CA Cancer J Clin
– volume: 22
  start-page: 65
  year: 2008
  end-page: 73
  article-title: Chronic inflammation and pancreatic cancer
  publication-title: Best Prac Res Clin Gastroenterol
– volume: 23
  start-page: 265
  year: 2012
  end-page: 273
  article-title: Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer
  publication-title: J Gynecol Oncol
– volume: 6
  start-page: 283
  year: 2003
  end-page: 287
  article-title: Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor
  publication-title: Angiogenesis
– volume: 212
  start-page: 199
  year: 1996
  end-page: 207
  article-title: Expression of thrombospondin‐1 in cancer: a role in tumor progression
  publication-title: Proc Soc Exp Biol Med
– volume: 223
  start-page: 147
  year: 1996
  end-page: 153
  article-title: Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy
  publication-title: Ann Surg
– volume: 246
  start-page: 52
  year: 2007
  end-page: 60
  article-title: Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma
  publication-title: Ann Surg
– volume: 29
  start-page: 16
  year: 1999
  end-page: 22
  article-title: The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection
  publication-title: Surg Today
– volume: 369
  start-page: 1691
  year: 2013
  end-page: 1703
  article-title: Increased survival in pancreatic cancer with nab‐paclitaxel plus gemcitabine
  publication-title: N Engl J Med
– volume: 420
  start-page: 860
  year: 2002
  end-page: 867
  article-title: Inflammation and cancer
  publication-title: Nature
– volume: 198
  start-page: 737
  year: 2004
  end-page: 741
  article-title: Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma
  publication-title: J Am Coll Surg
– volume: 454
  start-page: 436
  year: 2008
  end-page: 444
  article-title: Cancer‐related inflammation
  publication-title: Nature
– volume: 22
  start-page: 913
  year: 2002
  end-page: 922
  article-title: Role of blood platelets in infection and inflammation
  publication-title: J Interferon Cytokine Res
– volume: 32
  start-page: 22
  year: 2006
  end-page: 28
  article-title: Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome
  publication-title: Pancreas
– volume: 315
  start-page: 1650
  year: 1986
  end-page: 1659
  article-title: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing
  publication-title: N Engl J Med
– volume: 102
  start-page: 5
  year: 2001
  end-page: 14
  article-title: Ratio of neutrophil to lymphocyte counts – rapid and simple parameter of systemic inflammation and stress in critically ill
  publication-title: Bratisl Lek Listy
– volume: 109
  start-page: 416
  year: 2013
  end-page: 421
  article-title: Increased neutrophil‐lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
  publication-title: Br J Cancer
– volume: 17
  start-page: 52
  year: 2010
  end-page: 58
  article-title: The predictive value of pre‐treatment inflammatory markers in advanced non‐small‐cell lung cancer
  publication-title: Curr Oncol
– volume: 35
  start-page: 868
  year: 2011
  end-page: 872
  article-title: Preoperative neutrophil‐to‐lymphocyte ratio (NLR) is associated with reduced disease‐free survival following curative resection of pancreatic adenocarcinoma
  publication-title: World J Surg
– volume: 340
  start-page: 448
  year: 1999
  end-page: 454
  article-title: Acute‐phase proteins and other systemic responses to inflammation
  publication-title: N Engl J Med
– volume: 6
  start-page: 149
  year: 2010
  end-page: 163
  article-title: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer
  publication-title: Future Oncol
– volume: 23
  start-page: 195
  year: 2004
  end-page: 200
  article-title: Immunodeficiency in different histotypes of radically operable gastrointestinal cancers
  publication-title: J Exp Clin Cancer Res
– volume: 71
  start-page: 29
  year: 1998
  end-page: 37
  article-title: The effects of platelet‐derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium
  publication-title: Gynecol Oncol
– ident: e_1_2_6_2_1
  doi: 10.3322/caac.20107
– ident: e_1_2_6_38_1
  doi: 10.1056/NEJMoa1110352
– ident: e_1_2_6_22_1
  doi: 10.1016/j.amjsurg.2009.08.041
– ident: e_1_2_6_40_1
  doi: 10.1016/j.ctrv.2012.08.003
– ident: e_1_2_6_34_1
  doi: 10.1089/10799900260286623
– ident: e_1_2_6_8_1
  doi: 10.1007/BF02482964
– ident: e_1_2_6_19_1
  doi: 10.3802/jgo.2012.23.4.265
– ident: e_1_2_6_20_1
  doi: 10.3747/co.v17i4.567
– ident: e_1_2_6_7_1
  doi: 10.1097/01.sla.0000259391.84304.2b
– ident: e_1_2_6_9_1
  doi: 10.1056/NEJM198612253152606
– ident: e_1_2_6_25_1
  doi: 10.1056/NEJM199902113400607
– ident: e_1_2_6_27_1
  doi: 10.1023/B:AGEN.0000029415.62384.ba
– ident: e_1_2_6_16_1
  doi: 10.1007/s00268-011-0984-z
– volume: 102
  start-page: 5
  year: 2001
  ident: e_1_2_6_26_1
  article-title: Ratio of neutrophil to lymphocyte counts – rapid and simple parameter of systemic inflammation and stress in critically ill
  publication-title: Bratisl Lek Listy
  contributor:
    fullname: Zahorec R
– ident: e_1_2_6_10_1
  doi: 10.1038/nature01322
– volume: 85
  start-page: 1001
  year: 1984
  ident: e_1_2_6_21_1
  article-title: [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]
  publication-title: Nihon Geka Gakkai Zasshi
  contributor:
    fullname: Onodera T
– ident: e_1_2_6_28_1
  doi: 10.1016/j.jhep.2012.08.017
– ident: e_1_2_6_14_1
  doi: 10.1016/j.critrevonc.2013.03.010
– ident: e_1_2_6_24_1
  doi: 10.1016/j.cell.2011.02.013
– ident: e_1_2_6_31_1
  doi: 10.1016/S0002-9440(10)65149-8
– volume: 14
  start-page: 657
  year: 1994
  ident: e_1_2_6_6_1
  article-title: Malignant tumors in the head of the pancreas and the periampullary region. Diagnostic and prognostic aspects
  publication-title: Anticancer Res
  contributor:
    fullname: Griffanti‐Bartoli F
– ident: e_1_2_6_11_1
  doi: 10.1016/S0140-6736(00)04046-0
– ident: e_1_2_6_35_1
  doi: 10.1016/j.jamcollsurg.2004.01.022
– ident: e_1_2_6_37_1
  doi: 10.1006/gyno.1998.5121
– ident: e_1_2_6_30_1
  doi: 10.1016/j.cytogfr.2007.01.015
– ident: e_1_2_6_5_1
  doi: 10.1097/00000658-199602000-00006
– ident: e_1_2_6_17_1
  doi: 10.1007/s12032-012-0226-8
– volume: 23
  start-page: 195
  year: 2004
  ident: e_1_2_6_32_1
  article-title: Immunodeficiency in different histotypes of radically operable gastrointestinal cancers
  publication-title: J Exp Clin Cancer Res
  contributor:
    fullname: Romano F
– ident: e_1_2_6_15_1
  doi: 10.1038/sj.bjc.6606087
– ident: e_1_2_6_4_1
  doi: 10.1056/NEJMoa1304369
– ident: e_1_2_6_39_1
  doi: 10.2217/fon.09.136
– ident: e_1_2_6_29_1
  doi: 10.1097/01.mpa.0000188305.90290.50
– ident: e_1_2_6_36_1
  doi: 10.3181/00379727-212-44008
– ident: e_1_2_6_3_1
  doi: 10.1056/NEJMoa1011923
– ident: e_1_2_6_12_1
  doi: 10.1038/nature07205
– ident: e_1_2_6_23_1
  doi: 10.1038/bjc.2013.332
– ident: e_1_2_6_33_1
  doi: 10.1097/00000421-200304000-00007
– ident: e_1_2_6_18_1
  doi: 10.1016/j.amjsurg.2007.12.057
– ident: e_1_2_6_13_1
  doi: 10.1016/j.bpg.2007.11.007
– ident: e_1_2_6_41_1
  doi: 10.1038/bjc.2011.100
SSID ssj0017394
Score 2.424749
Snippet Background The prognostic significance of various systemic inflammation‐based markers has been explored in different cancers. These markers can be used to...
The prognostic significance of various systemic inflammation-based markers has been explored in different cancers. These markers can be used to assist with...
Abstract Background The prognostic significance of various systemic inflammation‐based markers has been explored in different cancers. These markers can be...
BACKGROUNDThe prognostic significance of various systemic inflammation-based markers has been explored in different cancers. These markers can be used to...
SourceID proquest
crossref
pubmed
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 676
SubjectTerms Adult
Aged
Aged, 80 and over
biomarker
Biomarkers - blood
cancer
chemotherapy
Female
Humans
inflammation
Inflammation - blood
Inflammation - diagnosis
Inflammation - mortality
Inflammation Mediators - blood
Male
Middle Aged
pancreas
Pancreatic Neoplasms - blood
Pancreatic Neoplasms - diagnosis
Pancreatic Neoplasms - mortality
Prognosis
Retrospective Studies
Survival Rate - trends
Title Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer
URI https://api.istex.fr/ark:/67375/WNG-9FLQPGHR-C/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fimj.12453
https://www.ncbi.nlm.nih.gov/pubmed/24750233
https://search.proquest.com/docview/1547537402
Volume 44
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEB5CCksv3Xb7yvaBupSlF4fYlq2YnkpokoZNyIaG5FAQkixDWZIsecCyp_6E_sb-ks5IsWnKLpTejCTbkmZG-kYafQJ4n3L0jLVIgiLiOuBco0lphbqsolib0MRG0EHh4SjtT_lgnsxr8LE8C-P5IaoFN7IMN16TgSu9-cPIvy_QzCOeENMnEekRIJpU1FGhiN0liOgvcLcWsWcVoiie6s2DuegBdevNXUDzELe6iad7DN_KKvt4k6vmbqub5vYvNsf_bNNjeLQHpOyT16AnULPLEzga7rfcn8JsvF5RMB5mM2IGt2xVMM__jCmon6hS_vjjrx8_aU7M2YJCftYbzGRliAHDQcfjU8MMpayfwbT7-WunH-xvYwgMzllxkLVJfNwgwikikYrQpLylM6FsSJcqxAWPWzkCOtvKCyHaPEvRc0F5K8WJoyeLn0N9uVral8AyZVOV8xRzFA_ztipEEemsZa1OMlXEDTgr5SKvPemGLJ0V7CLpuqgB505iVQlsG0WpiUTORj2ZdS8ux73-RHYa8K4UqUTboQ0RtbSr3UYifERvTaAL3YAXXtbV1yLMQjyDv_ngJHZ_ReSX4cA9nP570VfwEJEX93G_r6G-Xe_sG0Q3W_3WqfFvl_T0xQ
link.rule.ids 315,786,790,1382,27957,27958,46329,46753
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fa9swED-6Frq-dP23Lt26qmWMvbjElmzFsJdRmiZpErqSkLwMIckyjJFk5A-UPu0j7DP2k_QkxWYtHZS-GZ1sS7o73e-k0wngU8LQM1Y8DvKIqYAxhSqlJMqyjKjSoaaa24PCnW7S6LPWMB6uwNfiLIzPD1EuuFnNcPO1VXC7IP2Plv8coZ5HLKavYA3VPXYO1XWZPCrk1F2DiB4Dc6sRy7xCNo6nfPWBNVqzA3vzFNR8iFyd6am_gR9Fo33Eya_TxVyd6ttH-Rxf2qst2FxiUvLNC9E2rJjxDqx3lrvuuzC4mk5sPB6SiU0ObsgkJz4FNJagiKJU-ROQd3_-WrOYkZGN-pnOkEiKKAOC846HqJpoWzLdg379vHfWCJYXMgQazRYN0prlINMIcvKIJzzUCauqlEsT2nsVaM5oNUNMZ6pZznmNpQk6L8hyKZlN05PSt7A6nozNOyCpNInMWIIUycKsJnOeRyqtGqPiVOa0AicFY8Rvn3dDFP4KDpFwQ1SBz45lZQ3smw1U47EYdC9EWm9_v7poXIuzChwXPBWoPnZPRI7NZDETiCBRcjh60RXY98wuvxYhCSEN_uaLY9n_GyKanZZ7OHh-1SN43eh12qLd7F6-hw0EYsyHAX-A1fl0YQ4R7MzVRyfT9_Mq-Oc
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dSxwxEB-sgvTF-tHq1Y9GKaUve9xusptbfBL1PD_uuEpFH4SQZBMQ8U7OOyh98k_wb_QvcZLcLioVim9LJrubZGYyv0kmE4DvGUPPWPE0sglTEWMKVUpJlGWZUKVjTTV3B4U73ax9xo4u0osp2C7PwoT8ENWCm9MMP187Bb8t7DMlv7pBNU9YSj_ADMto4kR677TKHRVz6m9BRIeB-cWISVohF8ZTvfrCGM24cf3zL6T5Erh6y9P6BJdlm0PAyXV9PFJ1_fdVOsd3dmoe5iaIlOwEEVqAKdNfhNnOZM99Cc57w4GLxkMycanBDRlYEhJAYwkKKMpUOP_4eP_gjGJBblzMz_AOiaSMMSA46wSAqol2JcPPcNba_73bjibXMUQajRaN8qbjH9MIcWzCMx7rjDVUzqWJ3a0K1DLaKBDRmUZhOW-yPEPXBRkuJXNJenL6Bab7g75ZAZJLk8mCZUiRLC6a0nKbqLxhjEpzaWkNtkq-iNuQdUOU3goOkfBDVIMfnmNVDeybC1PjqTjvHoi8dfKrd9A-Fbs12CxZKlB53I6I7JvB-E4gfkR3jaMPXYPlwOvqawmSENDgb356jr3dEHHYOfIPX_-_6jeY7e21xMlh93gVPiIKYyEGeA2mR8OxWUekM1IbXqKfABQE95Y
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+value+of+systemic+inflammation-based+markers+in+advanced+pancreatic+cancer&rft.jtitle=Internal+medicine+journal&rft.au=Martin%2C+H+L&rft.au=Ohara%2C+K&rft.au=Kiberu%2C+A&rft.au=Van+Hagen%2C+T&rft.date=2014-07-01&rft.eissn=1445-5994&rft.volume=44&rft.issue=7&rft.spage=676&rft.epage=682&rft_id=info:doi/10.1111%2Fimj.12453&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1444-0903&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1444-0903&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1444-0903&client=summon